Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro

1 Y. Wang, S. Zou, Z. Zhao, P. Liu, C. Ke and S. Xu, New insights into small-cell lung cancer development and therapy, Cell Biol. Int. 44(8) (2020) 1564–1576; https://doi.org/10.1002/cbin.11359 Search in Google Scholar

2 A. Pavan, I. Attili, G. Pasello, V. Guarneri, P. F. Conte and L. Bonanno, Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges, J. Immunother. Cancer 7(1) (2019) Article ID 205 (13 pages); https://doi.org/10.1186/s40425-019-0690-1 Search in Google Scholar

3 F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre and A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, C. A. Cancer J. Clin. 68(6) (2018) 394–424; https://doi.org/10.3322/caac.21492 Search in Google Scholar

4 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, C. A. Cancer J. Clin. 71(3) (2021) 209–249; https://doi.org/10.3322/caac.21660 Search in Google Scholar

5 P. Goldstraw, Updated staging system for lung cancer, Surg. Oncol. Clin. N. Am. 20(4) (2011) 655–666; https://doi.org/10.1016/j.soc.2011.07.005 Search in Google Scholar

6 G. P. Kalemkerian, Small cell lung cancer, Semin. Respir. Crit. Care Med. 37(5) (2016) 783–796; https://doi.org/10.1055/s-0036-1592116 Search in Google Scholar

7 E. B. Bernhardt and S. I. Jalal, Small cell lung cancer, Cancer Treat. Res. 170 (2016) 301–322; https://doi.org/10.1007/978-3-319-40389-2_14 Search in Google Scholar

8 G. P. Kalemkerian and B. J. Schneider, Advances in small cell lung cancer, Hematol. Oncol. Clin. North Am. 31(1) (2017) 143–156; https://doi.org/10.1016/j.hoc.2016.08.005 Search in Google Scholar

9 S. Sundstrom, R. M. Bremnes, S. Kaasa, U. Aasebo, R. Hatlevoll, R. Dahle, N. Boye, M. Wang, T. Vigander, J. Vilsvik, E. Skovlund, E. Hannisdal, S. Aamdal and G. Norwegian, Lung cancer study: Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years’ follow-up, J. Clin. Oncol. 20(24) (2002) 4665–4672; https://doi.org/10.1200/JCO.2002.12.111 Search in Google Scholar

10 M. Takada, M. Fukuoka, M. Kawahara, T. Sugiura, A. Yokoyama, S. Yokota, Y. Nishiwaki, K. Watanabe, K. Noda, T. Tamura, H. Fukuda and N. Saijo, Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104, J. Clin. Oncol. 20(14) (2002) 3054–3060; https://doi.org/10.1200/JCO.2002.12.071 Search in Google Scholar

11 R. L. Siegel, K. D. Miller, H. E. Fuchs and A. Jemal, Cancer statistics, 2021, C. A. Cancer J. Clin. 71(1) (2021) 7–33; https://doi.org/10.3322/caac.21654 Search in Google Scholar

12 T. F. Mott, Lung cancer: Management, F. P. Essent. 464 (2018) 27–30. Search in Google Scholar

13 G. S. Jones and D. R. Baldwin, Recent advances in the management of lung cancer, Clin. Med. (Lond). 18(Suppl 2) (2018) s41-s46; https://doi.org/10.7861/clinmedicine.18-2-s41 Search in Google Scholar

14 C. Ma, J. Tang, H. Wang, G. Tao, X. Gu and L. Hu, Preparative purification of salidroside from Rhodiola rosea by two-step adsorption chromatography on resins, J. Sep. Sci. 32(2) (2009) 185–191; https://doi.org/10.1002/jssc.200800438 Search in Google Scholar

15 A. Kucinskaite, V. Briedis and A. Savickas, Experimental analysis of therapeutic properties of Rhodiola rosea L. and its possible application in medicine, Medicina (Kaunas) 40(7) (2004) 614–619. Search in Google Scholar

16 Y. Li, J. Wu, R. Shi, N. Li, Z. Xu and M. Sun, Antioxidative effects of Rhodiola genus: Phytochemistry and pharmacological mechanisms against the diseases, Curr. Top. Med. Chem. 17(15) (2017) 1692–1708; https://doi.org/10.2174/1568026617666161116141334 Search in Google Scholar

17 S. N. Udintsev and V. P. Shakhov, Decrease in the growth rate of Ehrlich’s tumor and Pliss’ lymphosarcoma with partial hepatectomy, Vopr. Onkol. 35(9) (1989) 1072–1075. Search in Google Scholar

18 H. Zhang, C. Ding, Y. Li, C. Xing, S. Wang, Z. Yu, L. Chen, P. Li and M. Dai, Data mining-based study of collagen type III alpha 1 (COL3A1) prognostic value and immune exploration in pan-cancer, Bioengineered 12(1) (2021) 3634–3646; https://doi.org/10.1080/21655979.2021.1949838 Search in Google Scholar

19 X. Xin, D. Yao, K. Zhang, S. Han, D. Liu, H. Wang, X. Liu, G. Li, J. Huang and J. Wang, Protective effects of rosavin on bleomycin-induced pulmonary fibrosis via suppressing fibrotic and inflammatory signaling pathways in mice, Biomed. Pharmacother. 115 (2019) Article ID 108870 (8 pages); https://doi.org/10.1016/j.biopha.2019.108870 Search in Google Scholar

20 W. X. Peng, J. G. Huang, L. Yang, A. H. Gong and Y. Y. Mo, Linc-RoR promotes MAPK/ERK signaling and confers estrogen-independent growth of breast cancer, Mol. Cancer 16(1) (2017) Article ID 161 (11 pages); https://doi.org/10.1186/s12943-017-0727-3 Search in Google Scholar

21 M. Pashirzad, R. Khorasanian, M. M. Fard, M. H. Arjmand, H. Langari, M. Khazaei, S. Soleiman-pour, M. Rezayi, G. A. Ferns, S. M. Hassanian and A. Avan, The therapeutic potential of MAPK/ERK inhibitors in the treatment of colorectal cancer, Curr. Cancer Drug Targets 21(11) (2021) 932–943; https://doi.org/10.2174/1568009621666211103113339 Search in Google Scholar

22 B. Wang, X. X. Zhu, L. Y. Pan, H. F. Chen and X. Y. Shen, PP4C facilitates lung cancer proliferation and inhibits apoptosis via activating MAPK/ERK pathway, Pathol. Res. Pract. 216(5) (2020) Article ID 152910; https://doi.org/10.1016/j.prp.2020.152910 Search in Google Scholar

23 Z. Wang, G. Kan, C. Sheng, C. Yao, Y. Mao and S. Chen, ARHGEF19 regulates MAPK/ERK signaling and promotes the progression of small cell lung cancer, Biochem. Biophys. Res. Commun. 533(4) (2020) 792–799; https://doi.org/10.1016/j.bbrc.2020.09.085 Search in Google Scholar

24 Y. Liu, Z. Zhang, T. Song, F. Liang, M. Xie and H. Sheng, Resistance to BH3 mimetic S1 in SCLC cells that up-regulate and phosphorylate Bcl-2 through ERK1/2, Br. J. Pharmacol. 169(7) (2013) 1612–1623; https://doi.org/10.1111/bph.12243 Search in Google Scholar

25 S. Cristea and J. Sage, Is the canonical RAF/MEK/ERK signaling pathway a therapeutic target in SCLC?, J. Thorac. Oncol. 11(8) (2016) 1233–1241; https://doi.org/10.1016/j.jtho.2016.04.018 Search in Google Scholar

26 A. S. Marchev, P. Dimitrova, I. K. Koycheva and M. I. Georgiev, Altered expression of TRAIL on mouse T cells via ERK phosphorylation by Rhodiola rosea L. and its marker compounds, Food Chem. Toxicol. 108(Pt B) (2017) 419–428; https://doi.org/10.1016/j.fct.2017.02.009 Search in Google Scholar

27 R. Ruiz-Cordero and W. P. Devine, Targeted therapy and checkpoint immunotherapy in lung cancer, Surg. Pathol. Clin. 13(1) (2020) 17–33; https://doi.org/10.1016/j.path.2019.11.002 Search in Google Scholar

28 E. C. Naylor, J. K. Desani and P. K. Chung, Targeted therapy and immunotherapy for lung cancer, Surg. Oncol. Clin. N. Am. 25(3) (2016) 601–609; https://doi.org/10.1016/j.soc.2016.02.011 Search in Google Scholar

29 R. M. Montiel-Ruiz, M. E. Gonzalez-Trujano and M. Deciga-Campos, Synergistic interactions between the antinociceptive effect of Rhodiola rosea extract and B vitamins in the mouse formalin test, Phytomedicine 20(14) (2013) 1280–1287; https://doi.org/10.1016/j.phymed.2013.07.006 Search in Google Scholar

30 M. Deciga-Campos, M. E. Gonzalez-Trujano, R. Ventura-Martinez, R. M. Montiel-Ruiz, G. E. Angeles-Lopez and F. Brindis, Antihyperalgesic activity of Rhodiola rosea in a diabetic rat model, Drug Dev. Res. 77(1) (2016) 29–36; https://doi.org/10.1002/ddr.21289 Search in Google Scholar

31 Z. Liu, X. Li, A. R. Simoneau, M. Jafari and X. Zi, Rhodiola rosea extracts and salidroside decrease the growth of bladder cancer cell lines via inhibition of the mTOR pathway and induction of auto-phagy, Mol. Carcinog. 51(3) (2012) 257–267; https://doi.org/10.1002/mc.20780 Search in Google Scholar

32 A. Majewska, G. Hoser, M. Furmanowa, N. Urbanska, A. Pietrosiuk, A. Zobel and M. Kuras, Anti-proliferative and antimitotic effect, S phase accumulation and induction of apoptosis and necrosis after treatment of extract from Rhodiola rosea rhizomes on HL-60 cells, J. Ethnopharmacol. 103(1) (2006) 43–52; https://doi.org/10.1016/j.jep.2005.05.051 Search in Google Scholar

33 X. Hu, S. Lin, D. Yu, S. Qiu, X. Zhang and R. Mei, A preliminary study: the anti-proliferation effect of salidroside on different human cancer cell lines, Cell Biol. Toxicol. 26(6) (2010) 499–507; https://doi.org/10.1007/s10565-010-9159-1 Search in Google Scholar

34 W. Zhang, W. Zhang, L. Huo, Y. Chai, Z. Liu, Z. Ren and C. Yu, Rosavin suppresses osteoclasto-genesis in vivo and in vitro by blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and mitogen-activated protein kinase (MAPK) signaling pathways, Ann. Transl. Med. 9(5) (2021) Article ID 383 (14 pages); https://doi.org/10.21037/atm-20-4255 Search in Google Scholar